Analysis of the Therapeutic and Clinical Profile of Cannabinoid Treatments: A Real-World Study
Enrolling by invitationNCT07362407
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
What is the purpose of this study? The use of medicinal cannabis has grown significantly in Brazil. However, because many patients use these products through "compassionate use" (when traditional treatments haven't worked), there is still a lack of large-scale data on how these treatments perform in daily life. This study, called CANAREAL, aims to track patients across Brazil to understand if cannabis-based products are truly effective and safe for treating various conditions, such as chronic pain, anxiety, and depression. How will the study work? This is an observational study, which means the researchers will not provide the medication or change the treatment prescribed by the patient's doctor. Instead, we will simply "follow" the patient's journey for 6 months. What will participants be asked to do? Participants will complete online questionnaires at different stages of their treatment. These tools will measure: Quality of Life: How the treatment affects daily well-being. Clinical Evolution: Changes in pain levels, anxiety, and depression symptoms. Safety: Whether the patient experiences any side effects (adverse events). Why is this study important? Unlike controlled laboratory tests, this "Real-World Study" captures the reality of diverse patients with different backgrounds and health needs. The information gathered will help doctors, patients, and health authorities in Brazil better understand the benefits and risks of cannabinoid therapy, leading to safer and more informed medical decisions in the future.
Study details
- Official title
- Analysis of the Therapeutic and Clinical Profile of Cannabinoid Treatments: A Real-World Study (CANAREAL)
- Conditions
- Chronic Pain
- Depression Disorders
- Anxiety Disorders
- Quality of Life
- Cannabidiol Effects
- Cannabinoids
- Interventions
- Dietary supplement: Participants are followed while using cannabis-based products (such as CBD or THC oils, extracts, or isolates) as prescribed by their own physicians for therapeutic purposes.
- Sponsor
- Santa Catarina Federal University
- Collaborators
- HempMeds Brasil
- Start date
- 2026-03-01
- Primary completion
- 2026-09
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Brazil
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients aged 18 years or older. * Residents of Brazil. * Patients who have a valid medical prescription for cannabis-based products. * Patients who are either starting a new treatment or are already using cannabinoid products under the ANVISA RDC 660/22 or RDC 327/19 regulations. * Capability to understand and sign the Informed Consent Form (ICF). * Access to a smartphone or computer with internet to complete the digital follow-up questionnaires. Exclusion Criteria: * Patients who do not agree to the terms of the Informed Consent Form (ICF). * Patients who fail to complete the initial (Baseline/T0) sociodemographic and clinical questionnaires. * Inability to communicate.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07362407